The aim of this study, therefore, was to explore whether there was an association between doses of norepinephrine to maintain mean arterial pressure at ≈80 mmHg during cardiopulmonary bypass and cerebral oxygen saturation measured using near-infrared spectroscopy.
On the other hand, in the presence of mouse Gal-Hyl264 the stimulating intensity varied between T-cell hybridomas and doses of at least 25 μmol/l were required to induce detectable responses (not shown).
There were no differences (P≥0.05) in most growth parameters between the doses of xylanase at 1200, 2400 and 3600 U/kg.
After the 1 year extension with ranibizumab as needed in all groups, there was no difference between the doses of ranibizumab at 24 months.
An exploratory analysis indicated that the difference between placebo and both doses of quetiapine at the end of treatment increased with initial severity (i.e., baseline MADRS total score).
For β-lactams and carbapenem, the blood concentration should be maintained for >90-100% of the between-dose interval above MIC, at least in the case of severe infection [ 74, 75].
In accordance with previous studies in early arthritis, we did not find a significant correlation between cumulative doses of GCs and BMD variation at the lumbar spine or hip [ 18, 19, 26].
During cooling to 30°C and 28°C, no differences were observed in HR between groups, but the differences in hemodynamic responses between the two doses of Epi became manifest at 30°C, at which Epi infusion at 0.125 μg/min significantly (P < 0.05) increased SV and CO when compared with both Epi infusion at 1.25 μg/min and saline infusion.
There have been many positive studies across various chronic pain syndromes, showing benefit of THC in trials with smoked or vaporized cannabis comparing between different doses of THC, with benefit often noted at higher percentages [28, 47, 157 169].
The planned sample size of ~100 was sufficient for a one-sided 75% CI upper bound of −0.68% in HbA1c mean change from baseline difference between LY and placebo at end of dosing, assuming a dropout rate of 30%, SD of 0.8%, and mean change from baseline difference between LY and placebo at end of dosing of at least −0.87% HbA1c.
